Various pharmacological agents in the pipeline against intractable epilepsy
Abdul Waris,Muhammad Asim,Ata Ullah,Fahad A. Alhumaydhi
DOI: https://doi.org/10.1002/ardp.202400229
2024-05-22
Archiv der Pharmazie
Abstract:This review provides a comprehensive overview of the various treatment options and agents, especially pharmacological agents, in various phases of clinical trials against intractable or drug‐resistant epilepsy. Epilepsy is a noncommunicable chronic neurological disorder affecting people of all ages, with the highest prevalence in low and middle‐income countries. Despite the pharmacological armamentarium, the plethora of drugs in the market, and other treatment options, 30%–35% of individuals still show resistance to the current medication, termed intractable epilepsy/drug resistance epilepsy, which contributes to 50% of the mortalities due to epilepsy. Therefore, the development of new drugs and agents is needed to manage this devastating epilepsy. We reviewed the pipeline of drugs in "ClinicalTrials. gov," which is the federal registry of clinical trials to identify drugs and other treatment options in various phases against intractable epilepsy. A total of 31 clinical trials were found regarding intractable epilepsy. Among them, 48.4% (15) are about pharmacological agents, of which 26.6% are in Phase 1, 60% are in Phase 2, and 13.3% are in Phase 3. The mechanism of action or targets of the majority of these agents are different and are more diversified than those of the approved drugs. In this article, we summarized various pharmacological agents in clinical trials, their backgrounds, targets, and mechanisms of action for the treatment of intractable epilepsy. Treatment options other than pharmacological ones, such as devices for brain stimulation, ketogenic diets, gene therapy, and others, are also summarized.
pharmacology & pharmacy,chemistry, medicinal, multidisciplinary